Physician profile
Bryan Daniel Ellertson
NPI 1881989143
$1,918.42
in general payments reported to CMS, 2019-2025
37 companies · $127 in 2025
The $127 reported for 2025 was more than what a typical Pediatrics provider received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $476 · 2020: $134 · 2021: $394 · 2022: $334 · 2023: $287 · 2024: $166 · 2025: $127.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $580.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $580.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $310.96 | 2019-2025 | Shingrix, Arexvy, Bexsero |
| Boehringer Ingelheim Pharmaceuticals, INC. | $248.14 | 2019-2023 | Tradjenta, Synjardy, Jardiance |
| Takeda Pharmaceuticals U.S.A., INC. | $139.88 | 2019-2024 | Trintellix |
| Amgen INC. | $136.44 | 2019 | |
| Cranial Technologies, INC | $86.39 | 2019-2025 | Doc Band |
| Dynavax Technologies Corporation | $79.52 | 2019-2023 | Heplisav-B |
| Lilly USA, LLC | $78.61 | 2019-2023 | Jardiance |
| Merck Sharp & Dohme LLC | $71.44 | 2019-2022 | |
| Pfizer INC. | $64.36 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $62.48 | 2019-2023 | Spravato |
| Amarin Pharma, INC. | $56.31 | 2021 | |
| Kyowa Kirin, INC. | $53.55 | 2023-2025 | Crysvita |
| Tris Pharma INC | $51.51 | 2022-2025 | Quillivant |
| Smith+Nephew, INC. | $51.25 | 2024 | Collagenase Santyl, Iodosorb Ointment 40g USA |
| Shire North American Group INC | $41.20 | 2019 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shield Therapeutics INC | $32.47 | 2023 | Accrufer |
| Upsher-Smith Laboratories LLC | $29.16 | 2020-2021 | |
| Novo Nordisk INC | $28.73 | 2022-2025 | |
| Dexcom, INC. | $23.13 | 2025 | Dexcom G6 Transmitter |
| Ironshore Pharmaceuticals INC. | $19.89 | 2024 | |
| Biohaven Pharmaceutical Holding Company LTD. | $19.11 | 2022 | |
| Astellas Pharma US INC | $18.86 | 2021 | |
| Phadia US INC. | $18.20 | 2021 | |
| Organon LLC | $15.86 | 2022-2023 | Nexplanon |
| Janssen Biotech, INC. | $15.61 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $15.59 | 2019 | |
| Abbvie INC. | $15.02 | 2023 | |
| Sanofi Pasteur INC. | $14.97 | 2021 | |
| Eisai INC. | $14.88 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $14.61 | 2022 | |
| Halozyme INC | $13.81 | 2023 | |
| Inspire Medical Systems, INC. | $13.69 | 2024 | Inspire |
| Ascensia Diabetes Care US INC. | $13.65 | 2025 | |
| Currax Pharmaceuticals LLC | $12.44 | 2022 | |
| Seqirus USA INC | $12.33 | 2021 | |
| Bioventus LLC | $12.22 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $12.15 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bryan Ellertson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.